39 results on '"Mirallas O"'
Search Results
2. 29O Clinical characterization of long-term survivors in phase I clinical trials
3. 99P Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis
4. 93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)
5. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
6. 250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)
7. 115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)
8. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST
9. 1872P Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center
10. 1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
11. 1008P Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
12. 664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
13. 493P The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
14. 457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
15. 445MO Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial
16. 503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
17. 2150P Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
18. 2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
19. 2137P Impact of supportive care on the quality of life (QoL) of hospitalized cancer patients (pts)
20. 473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
21. P-327 Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma
22. P-284 Stereotactic body radiotherapy (SBRT) for liver metastasis of colorectal and anal cancer patients: Clinical outcomes of a single centre experience
23. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
24. 350P Postoperative histopathological, clinical and molecular risk score for patients with colorectal liver metastases
25. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)
26. 126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)
27. 1724P Prognostic parameters at admission as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts) of a tertiary hospital
28. 1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection
29. 1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
30. 318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
31. 1713P Active smoking and severity of COVID-19 infection in cancer patients
32. 1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital
33. 1681P First results of the COCO study: COVID-19 outcomes in patients with cancer
34. 1858P Role of depression and quality of life (QOL) status as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts)
35. 938P Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
36. 167P - Efficacy of Cetuximab Based Chemotherapy after Immunotherapy Treatments (IT) in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Patients (pts)
37. 69P - Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
38. 823P - Molecular subtypes of metastatic (met) gastric cancer (GC) (MoTriGastric): New biomarkers closer to the clinics
39. 566P - Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.